Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RJK-RT2831
- Development stage
- Phase 1
- Lead developer
- Nanjing RegeneCore Biotech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RJK-RT2831 is a bispecific nanobody drug developed by Nanjing RegeneCore Biotech. It is designed to target specific antigens on the surface of malignant blood tumor cells, with the aim of treating hematologic neoplasms and other cancers. The drug has demonstrated promising safety and efficacy in preclinical studies. As of 2024, it has received Investigational New Drug (IND) approval from both the US FDA and China's State Food and Drug Administration for clinical trials in oncology indications, specifically hematologic malignancies. The mechanism of action involves dual targeting via its bispecific nanobody structure, but the precise molecular targets have not been publicly disclosed[3][7][5].
- Other names
- RT2831RT-2831RT 2831
Beyond the preview
Go deeper on RJK-RT2831.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RJK-RT2831.